Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Heinz Grunze, Eduard Vieta, Guy M. Goodwin, Charles Bowden, Rasmus W. Licht, Jean-Michel Azorin, Lakshmi Yatham, Sergey Mosolov, Hans-Jürgen Möller & Siegfried Kasper. (2018) The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long-term treatment of mixed states in bipolar disorder. The World Journal of Biological Psychiatry 19:1, pages 2-58.
Read now
Read now
Heinz Grunze, Eduard Vieta, Guy M. Goodwin, Charles Bowden, Rasmus W. Licht, Hans-Jürgen Möller & Siegfried Kasper. (2013) The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2012 on the long-term treatment of bipolar disorder. The World Journal of Biological Psychiatry 14:3, pages 154-219.
Read now
Read now
Carla M Canuso & Wendy P Battisti. (2010) Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania. Expert Opinion on Pharmacotherapy 11:15, pages 2557-2567.
Read now
Read now
Camilla Haw & Jean Stubbs. (2007) Off-label use of antipsychotics: are we mad?. Expert Opinion on Drug Safety 6:5, pages 533-545.
Read now
Read now
Richard C Shelton. (2006) The return of fixed combinations in psychiatry: fluoxetine and olanzapine combination. Therapeutics and Clinical Risk Management 2:2, pages 187-192.
Read now
Read now
Articles from other publishers (7)
Nicholas M Wallingford, Puspha Sinnayah, Frank P Bymaster, Kishore M Gadde, Ranga K Krishnan, Anthony A McKinney, Ronald P Landbloom, Gary D Tollefson & Michael A Cowley. (2008) Zonisamide Prevents Olanzapine-Associated Hyperphagia, Weight Gain, and Elevated Blood Glucose in Rats. Neuropsychopharmacology 33:12, pages 2922-2933.
Crossref
Crossref
Helen R. WinterWillie R. EarleyJennifer E. Hamer-MaanssonPatty C. DavisMark A. Smith. (2008) Steady-State Pharmacokinetic, Safety, and Tolerability Profiles of Quetiapine, Norquetiapine, and Other Quetiapine Metabolites in Pediatric and Adult Patients with Psychotic Disorders. Journal of Child and Adolescent Psychopharmacology 18:1, pages 81-98.
Crossref
Crossref
Scott D. Mendelson. 2008. Metabolic Syndrome and Psychiatric Illness. Metabolic Syndrome and Psychiatric Illness
73
91
.
Heinz Grunze & Anna Forsthoff. 2008. Handbuch der Psychopharmakotherapie. Handbuch der Psychopharmakotherapie
555
590
.
Susan L. McElroy, Trisha Suppes, Mark A. Frye, Lori L. Altshuler, Kevin Stanford, Brian Martens, Gabriele S. Leverich, Robert M. Post & Paul E. KeckJr.Jr.. (2007) Open-label aripiprazole in the treatment of acute bipolar depression: A prospective pilot trial. Journal of Affective Disorders 101:1-3, pages 275-281.
Crossref
Crossref
I. R. De Oliveira & M. F. Juruena. (2006) Treatment of psychosis: 30 years of progress. Journal of Clinical Pharmacy and Therapeutics 31:6, pages 523-534.
Crossref
Crossref
Henry A Nasrallah, Martin Brecher & Björn Paulsson. (2006) Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania. Bipolar Disorders 8:5p1, pages 467-474.
Crossref
Crossref